Page Tools:

Stroke Essentials 2010 iPhone App

Author(s): Adrian J. Goldszmidt, MD, Director, Cerebrovascular Program, Sinai Hospital, Instructor of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland
Louis R. Caplan, MD, Director of Cerebrovascular Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts, Professor of Neurology, Harvard Medical School, Boston, Massachusetts
Details:
  • ISBN-13: 9780763798703
  • ISBN-10:0763798703
  • Mobile     pages      © 2010
Price: International Sales $24.99 US List
Buy Now at the iTunes App Store

Overview

The second edition of Stroke Essentials 2010 is now available for iPhone, iTouch and iPad1.

The Stroke Essentials iPhone App is a concise, authoritative, and practical guide to the detection, evaluation, and treatment of stroke.  Primary and secondary prevention measures are emphasized, forming the basis for a management strategy aimed at halting the progression of atherosclerosis, stabilizing rupture-prone plaques, preventing arterial thromboembolism, and improving prognosis. Includes the latest guidelines, common pitfalls, a comprehensive film library, clinical management algorithms and a summary of important clinical trials. Cardiovascular risk reduction measures are also emphasized.

1iPad is supported through iPhone-compatibility mode.

ShowTable of Contents

SECTION 1: DIAGNOSIS, EVALUATION, AND
TREATMENT OF STROKE
 

1. Overview of Stroke
Classification
Detection and Evaluation of Stroke
History, Physical Exam, and Laboratory Testing
Imaging
• CT/MRI
• Doppler Ultrasound
• Magnetic Resonance and Computed
• Tomography Angiography
• Cerebral Angiography
• Lumbar Puncture
• Echocardiogram
• Electrocardiography
• Holter Monitoring
• Electroencephalography
 

2. Ischemic Stroke
Clinical Features
Overview of Treatment
Presentation
Lytic-eligible Patients
Lytic-ineligible Patients
• Antiplatelet Therapy
• Heparin Therapy
o Clinical Trials
o Recommendations
o Heparin Dose
Measures to Prevent Recurrent Stroke
Large Artery Atherothrombosis
• Internal Carotid Artery
• Vertebral Artery
• Intracranial Disease
Brain Embolism
• Atrial Fibrillation
• Acute Myocardial Infarction
• Valvular Heart Disease
• Cardiomyopathy
• Atrial Myxoma
• Paradoxical Embolism
• Other Cardiac Conditions
Lacunar Stroke
Transient Ischemic Attack
3. Thrombolytic Therapy for Ischemic Stroke
Overview
• Baseline Evaluation
Dosing and Administration
Post-lytic Care
• General Measures
Inclusion and Exclusion Criteria
Management of Elevated Blood Pressure
Management of Lytic Complications
NIH Stroke Scale

4. Brain Hemorrhage
Clinical Features
• Subarachnoid Hemorrhage

Ruptured Saccular (Berry) Aneurysm
• Overview
• Treatment

Ruptured AV Malformation
• Overview
• Treatment
• Complications
• Rebleeding
• Vasospasm
• Increased Intracranial Pressure
• Hydrocephalus

Intracerebral Hematoma
• Cardiac
• Hyponatremia

Intracerebral Hemorrhage
• Hypertension
• Other causes
• Cerebellar Hemorrhage
• Subdural and Extradural Hematoma

5. Stroke-Related Complications
Treatment
• Increased Intracranial Pressure
• Seizures
• Deep Venous Thrombosis
• Pulmonary Embolism
• Depression
• Hypertension
• Myocardial Infarction
• Arrhythmias
• Infections and Sepsis
• Upper Gl Bleed
• Hyponatremia
• Respiratory Depression
• Depressed Consciousness
• Fever
• Malnutrition
• Contractures
• Decubitus Ulcers

6. Miscellaneous Topics in Cerebrovascular Disease
Asymptomatic Carotid Artery Stenosis
• Stenosis >60%
• Stenosis <60%
Unruptured Aneurysm
Carotid Endarterectomy
Extracranial-intracranial Bypass
Carotid and Vertebral Artery Stenting

7. Stroke Pitfalls

8. Controversies in Stroke Management
Stroke and Patent Foramen Ovale
Antiplatelet Agents or Anticoagulation
• with Warfarin
• PFO Closure
Large Hemispheric Stroke within 3–6 Hours
• IV tPA
• IA tPA
• MERCI Retriever
Hemicraniectomy for Malignant MCAStroke
Craniotomy/Evacuation for Supratentorial ICH
• Benefi ts of Surgery
• Contraindications of Surgery
Antiplatelet Agents for Secondary Stroke Prevention
• Aspirin
• Clopidogrel or Aspirin and Extended Release Dipyridamole
Timing of Carotid Surgery After Recent Stroke
• Early vs Late
Acute Mild Stroke


SECTION 2: CEREBROVASCULAR & CARDIOVASCULAR RISK REDUCTION

9. Overview of Risk Reduction
• Annual Risk Percentage
• Modifiable Risk Factors

10. Therapeutic Lifestyle Changes
Diet Modification
• Therapeutic Lifestyle Changes Diet
• Recommendations
• Dietary Options for Risk Reduction
Mediterranean-Style Diet
• Mediterranean Diets
• Other Studies
• Recommendations
• Basic Components
• How to Incorporate
Physical Activity
• Overview
• Amount and Type of Exercise
• Stress Testing
Weight Control
• Overview
• Classifi cation of Obesity
• Evaluation of Obesity
• Treatment of Obesity
• Antiobesity Drugs Approved by the FDA
Smoking Cessation
• Overview
• Guidelines
• Strategies to Assist Patients to Quit
• Drug Therapy

11. Antiplatelet and AntithromboticTherapy to Prevent Recurrent Ischemic Stroke
Antiplatelet Therapy
Atherothrombosis as a Systemic Disease
Role of the Platelet
Antiplatelet Monotherapy
• Aspirin
• Clopidogrel
• Ticlopidine
Combination Antiplatelet Therapy
• Aspirin Plus Dipyridamole
• Aspirin Plus Clopidogrel
Summary
Antithrombotic Therapy

12. Control of Hypertension
Diagnosis and Evaluation
Proper Blood Pressure Measurement
Excluding Conditions Leading to Overdiagnosis
• White-coat Hypertension
• Pseudohypertension
Assessing Target Organ Damage
Secondary Hypertension
Treatment of Hypertension
Blood Pressure Goals
Drug Therapy
• Initial Therapy
• Intensifi cation of Therapy
• Combination Therapy
• Stepdown Therapy
Optimizing Patient Compliance

13. Control of Dyslipidemia
Diagnosis Evaluation and Treatment
• Lipoprotein Analysis
• Secondary Causes
• Genetic Dyslipidemia
• LDL/Non-HDL Cholesterol Goals
• Metabolic Syndrome
Treating Elevated LDL Cholesterol
Treating Low HDL Cholesterol
Treating Elevated Triglyceride
Drug Therapy for Dyslipidemia

14. Other Measures to Prevent Atherothrombosis and Stroke
Control of Diabetes Mellitus
ACE Inhibitors
Low-dose Fish Oil
Arterial Revascularization
• Carotid Endarterectomy
• Carotid Angioplasty and Stenting
Folic Acid
Antioxidants
Hormone Replacement Therapy
Citicoline


SECTION 3: CLINICAL TRIALS

Stroke Prophylaxis in Atrial Fibrillation (AF)
Antiplatelet/Antithrombotic Therapy for TIAs or Minor Strokes
Antiplatelet/Antithrombotic Therapy and Heparin for Acute Stroke
Randomized Thrombolysis Trials
Carotid Endarterectomy Trials
Cerebral Angioplasty/Stent Trials
Miscellaneous Stroke Trials
Hypertension Trials
Dyslipidemia and Other Risk Reduction Trials
Neuroprotection Trials
Intracerebral Hemorrhage Trials

SECTION 4: Film Library

References and Suggested Readings
Index
 


Back to top

ShowAbout the Author(s)

Adrian J. Goldszmidt, MD-Director, Cerebrovascular Program, Sinai Hospital, Instructor of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland

Adrian J. Goldszmidt, MD, is Director of the Cerebrovascular Disorders Program at Sinai Hospital and Instructor in Neurology at Johns Hopkins University Medical School, Baltimore, Maryland. After completing medical school at Harvard, he trained in Neurology at Harvard's Longwood program in Boston, then did a stroke fellowship at New England Medical Center. Dr. Goldszmidt has been an investigator in numerous acute stroke trials and has research interests in platelet function in stroke. He is actively involved in patient care., is Director of the Cerebrovascular Disorders Program at Sinai Hospital and Instructor in Neurology at Johns Hopkins University Medical School, Baltimore, Maryland. After completing medical school at Harvard, he trained in Neurology at Harvard's Longwood program in Boston, then did a stroke fellowship at New England Medical Center. Dr. Goldszmidt has been an investigator in numerous acute stroke trials and has research interests in platelet function in stroke. He is actively involved in patient care.
Additional Titles by this Author

Louis R. Caplan, MD-Director of Cerebrovascular Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts, Professor of Neurology, Harvard Medical School, Boston, Massachusetts

Louis R. Caplan, MD, is Director of Cerebrovascular Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Professor of Neurology, Harvard Medical School, Boston, Massachusetts; and one of the world’s leading authorities on stroke. During his distinguished career, he served as Chair of the Neurology Department at Beth Israel Hospital in Boston, Neurologist-in-Chief at Michael Reese Hospital in Chicago and the New England Medical Center in Boston, Professor of Neurology at the University of Chicago, and Professor and Chairman of the Department of Neurology and Professor of Medicine at Tufts Medical Center in Boston. He also served as Chairman of the Stroke Council of the American Heart Association and as chair of numerous neurological and stroke organizations. At Beth Israel Hospital, he founded the Harvard Stroke Registry. He is a diplomat of both the American Board of Internal Medicine and the American Board of Neurology and Psychiatry. He is the author or editor of 26 books, including the landmark textbook, Stroke: A Clinical Approach, now in its third edition, and he has contributed more than 500 scholarly articles to the medical literature. He also serves or has served on the editorial board of 21 medical journals. He speaks nationally and internationally on stroke and has delivered 18 named lectureships, including the 2000 Thomas Willis lecture for the American Heart Association. Dr.Caplan has received several teaching awards as well as the Distinguished Achievement Award from the American Heart Association.

Back to top